GlassScriptPhysician profile
Amber J Renn
NPI 1407903743
$3,081.80
in general payments reported to CMS, 2019-2025
30 companies · $89.64 in 2025
The $89.64 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $815 · 2022: $628 · 2023: $732 · 2024: $816 · 2025: $89.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $601.92 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $514.36 | 2021-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $361.11 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $174.69 | 2021-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.47 | 2021-2024 | Jardiance, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $121.60 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $116.10 | 2021-2023 | Shingrix, Arexvy |
| Mylan Specialty L.P. | $100.43 | 2021-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.87 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $95.53 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $76.90 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $71.60 | 2021-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $66.69 | 2023-2024 | |
| Pfizer INC. | $60.47 | 2023-2025 | |
| Eisai INC. | $55.66 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $51.22 | 2022-2025 | Contrave |
| Abbott Laboratories | $45.25 | 2022 | |
| Abbvie INC. | $37.62 | 2023-2025 | |
| Amarin Pharma, INC. | $32.67 | 2021 | |
| Mannkind Corporation | $31.78 | 2021 | |
| Daiichi Sankyo INC. | $27.76 | 2023 | Injectafer |
| Medtronic, INC. | $25.31 | 2025 | Mastergraft Matrix Ext |
| Dexcom, INC. | $22.50 | 2022 | |
| Bausch Health US, LLC | $21.83 | 2023 | Aplenzin |
| Genentech USA, INC. | $19.19 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.75 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.47 | 2024 | Voquezna |
| Antares Pharma, INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Renn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.